Search page

Clinical effects of dupilumab in patients with rhinosinusitis, nasal polyposis, and severe uncontrolled asthma with t2 phenotype, after 12 months of treatment

Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Comparative Gene Expression Analysis in Blood Samples and Nasal Polyps during Dupilumab Treatment for CRSwNP

Comparison of the proteomic profile in tears between patients with severe atopic dermatitis and severe asthma treated with Dupilumab

Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Dose reduction of dupilumab at 24 months of treatment in patients with controlled atopic dermatitis

Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis

Dupilumab Effect on Exacerbations and Lung Function Despite Withdrawal of Inhaled Corticosteroids/Long-acting Beta Agonists

Dupilumab Effectiveness Through Two Years in Patients with CRSwNP Treated in Real-World Practice: Results from the Global AROMA Registry

Dupilumab Efficacy in Allergic Bronchopulmonary Aspergillosis: a Case Report

Dupilumab Improves Lung Function and Reduces Exacerbation Frequency and IgE Levels in Patients with Asthma and Allergic Bronchopulmonary Aspergillosis (Phase 2 LIBERTY ABPA AIRED Study)

Dupilumab Improves Type 2 Inflammatory Biomarkers Over Time in Patients With Chronic Obstructive Pulmonary Disease

Dupilumab Improves Urticaria Activity, Health-Related Quality of Life, and Disease Perception and Severity in Patients with CSU: Results From the LIBERTY-CSU CUPID A Study

Dupilumab Is Efficacious in Children Aged 1–11 Years Weighing ≥15 kg With Eosinophilic Esophagitis Irrespective of Individual Atopic Comorbidities: 16-Week Results From the Phase 3 EoE KIDS Study

Dupilumab Reduces Exacerbations and Improves Asthma Control in Children With Moderate-to-Severe Type 2 Asthma, Regardless of Asthma Duration

Dupilumab Reduces FeNO levels and Exacerbations and Improves Asthma Control with Inhaled Corticosteroid Withdrawal: a Phase 2 Study

Dupilumab Reduces Patient-Reported Cough in Patients with SEA, CRSwNP, and SEA-CRSwNP: a Real-Life Study

Dupilumab Reduces Seasonal Exacerbation Rates in Children With Type 2 Asthma With or Without Evidence of Allergy

Dupilumab Reduces Systemic Corticosteroids in Children With Uncontrolled Moderate-to-Severe Asthma Regardless of Exacerbation History

Dupilumab Restores Barrier Function of Nasal Epithelial Cells and Decreases Type-2 Inflammatory Markers in Chronic Rhinosinusitis with Nasal Polyps

Dupilumab Treatment Reduces IgE Levels in Patients Aged 2 to 17 Years With Atopic Dermatitis, Asthma, and Eosinophilic Esophagitis

Dupilumab Treatment is Associated with Clinical Improvement and a Shift towards a health-associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis

Dupilumab alleviates the abnormal differentiation of club cells induced by IL-13 in chronic rhinosinusitis with nasal polyps

Dupilumab and emerging scores in children with Atopic Dermatitis: A 52 weeks monocentric prospective observational study

Dupilumab as a New Therapeutical Approach in Patients with Severe Seasonal Asthma Caused by Olive Pollen Sensitization

Dupilumab as effective treatment for chronic pruritus: a case report

Dupilumab decreases the number of days with dysphagia in adult and adolescent patients with eosinophilic esophagitis: post hoc analysis of LIBERTY EoE TREET study

Dupilumab dose reduction in controlled severe atopic dermatitis and predictive factors

Dupilumab efficacy in patients with an inadequate response, intolerance, or contraindication to swallowed topical corticosteroids: a subgroup analysis of data from the phase 3 LIBERTY EoE TREET study

Dupilumab for Treatment of Eosinophilic Gastrointestinal Disease in children

Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Dupilumab for the treatment of refractory severe chronic spontaneous urticaria

Dupilumab improves histologic and endoscopic outcomes in children aged 1–11 with eosinophilic esophagitis: Results from Part A of the Phase 3 EoE KIDS study

Dupilumab improves histologic, symptomatic, and endoscopic outcomes in children with eosinophilic esophagitis in the EoE KIDS study, regardless of history of elimination diet or concomitant food allergy

Dupilumab improves multiple histopathologic features of eosinophilic esophagitis over 52 weeks: Post hoc analysis of the phase 3 LIBERTY EoE TREET study

Dupilumab in Atopic dermatitis like eczema in IEI.

Dupilumab in Pediatric Patients with Severe Atopic Dermatitis: A Pilot Study

Dupilumab in Pediatric patients with moderate-to-severe Atopic Dermatitis

Dupilumab is Efficacious in Children (Aged 1 to <12 Years) With Eosinophilic Esophagitis Regardless of Prior History of Comorbidities

Dupilumab normalized the esophageal transcriptome in children aged 1 to <12 years with eosinophilic esophagitis (EoE) in the Phase 3 EoE KIDS trial

Dupilumab treatment effectively reduces nasal type 2 cytokine production following acetylsalicylic acid provocation in N-ERD patients

Dupilumab treatment leads to clinically meaningful improvements in a range of symptoms and quality of life in patients with eosinophilic esophagitis: Post hoc analysis of LIBERTY EoE TREET

Early Responders within One Month of Dupilumab Treatment for Chronic Rhinosinusitis with Nasal Polyps

Effect of Dupilumab on Radiological Remission in Patients with Chronic Rhinosinusitis with Nasal Polyp: A step Toward Clinical Remission

Effectiveness and Safety of Dupilumab in patients with chronic rhinosinusitis with nasal polyps After One Year of Therapy: Results from a real-world non-interventional study in Germany (ProGNOSE)

Effectiveness of Dupilumab in Severe CRSwNP: A Brazilian Study

Effectiveness of Dupilumab in improving Quality of Life in patients with “steroid-resistant” asthma and severe atopic dermatitis

Effects of Dupilumab on Eosinophil Subpopulations and Inflammation in Chronic Rhinosinusitis with Nasal Polyps

Effects of dupilumab on quality of life and airflow obstruction in refractory type 2 high severe unified airways disease

Efficacy and Safety of 1-Year Dupilumab Treatment in Children Aged 6-11 years with Moderate-to-Severe Atopic Dermatitis in South Korea: Multicenter Prospective Observational Study

Efficacy and Safety of Dupilumab in Children Aged 6 Months to 5 Years With Atopic Dermatitis With and Without Type 2 Comorbidities

Efficacy and injection schedule adjustment of Dupilumab in patients with chronic rhinosinusitis: Recent experiences in SNUH

Efficacy of Dupilumab by Baseline Disease Severity in Children Aged 6 to 11 Years With Uncontrolled Moderate-to-Severe Asthma: Post Hoc Results From the Randomized, Placebo-Controlled VOYAGE Trial

Efficacy of Dupilumab in patients over 50 years of age with severe asthma

Efficacy of dupilumab in atopic dermatitis with prurigo : a real-life study

Eosinophilia over dupilumab treatment in asthma patients: a multicentric retrospective study

Eosinophilic esophagitis in children and adolescents: clinical, endoscopic, histologic findings, and response to treatment with: fluticasone, budesonide, proton inhibitors and dupilumab

Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients With Uncontrolled Moderate-to-Severe Asthma: The VESTIGE Trial

Experience of dupilumab in difficult-to-treat eosinophilic esophagitis – A Case Series of 6 Portuguese Patients

First clinical practice of using biologic therapy with dupilumab in combination with allergen-specific immunotherapy in a patient with severe atopic dermatitis and bronchial asthma

Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab

Impact of Switching from Omalizumab to Dupilumab in Severe Asthma Patients: A Retrospective Evaluation of Efficacy and Inflammatory Biomarkers

Indirect case matched comparison of dupilumab versus benralizumab on mannitol airway hyperresponsiveness in type 2 high severe asthma

Initiation of dupilumab led to reduced use of corticosteroids and antibiotics over 12 months in patients with chronic rhinosinusitis with nasal polyps treated in US real world practice

Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis

Long term laboratory safety of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Long-Term Dupilumab Treatment is Not Associated With an Increased Overall Risk of Infections in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis in an Open-Label Extension Study

Long-term dupilumab effect on lung function in subgroups of pediatric patients with uncontrolled asthma

Longitudinal Outcome of Dupilumab for Children and Adolescents with Atopic Dermatitis: An Asian Perspective

Lung Function Responder Rates in the VOYAGE study in Children with Moderate-to-Severe Type 2 Asthma Receiving Dupilumab at Week 52

Nasal polyp CD62Llow eosinophils as a prognostic biomarker of chronic rhinosinusitis with nasal polyp severity and predictive biomarker of mepolizumab and dupilumab response

Nationwide Big Data Analysis of Atopic Dermatitis Treatments in Japan: Real-World Findings on the Impact of Dupilumab

PERSISTENT REDUCTION OF TOTAL SERUM IgE IN CRSwNP AFTER ESS WITH SHORT COURSE DUPILUMAB

Patients With Moderate-to-Severe Asthma Treated With Dupilumab Are More Likely to Meet Clinical Remission Criteria: Results From the VESTIGE Trial

Performance of 5 item and 22 item sino-nasal outcome tests in response to dupilumab in chronic rhinosinusitis with nasal polyps

Prevalence and impact of allergic comorbidities in patients with severe atopic dermatitis in treatment with Dupilumab

Proteomic Modulation by Dupilumab in Severe Seasonal Asthma: Insights from a Short-Term Treatment Study in Ole e 7-Sensitized Patients

Real-Life effectiveness of a Cohort of Patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Concomitant Moderate Persistent Asthma Treated with Dupilumab

Real-World Dupilumab Effectiveness Through 18 Months in Patients with CRSwNP and Coexisting Asthma: Results from the Global AROMA Registry

Real-life efficacy of dupilumab in patients with asthma phenotype overlap- data from a tertiary pulmonary centre

Real-world clinical experience with dupilumab use in 33 children with severe atopic dermatitis

Real-world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years

Real-world effectiveness of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is independent of comorbidities, sinus surgery history and level of type 2 inflammation: Findings from CHRINOSOR

Real-world efficacy of dupilumab as a second-line treatment in severe asthma- data from a tertiary pulmonary centre

Reduction in Oral Corticosteroid Burden in Patients With Moderate-to-Severe Asthma Initiating Dupilumab in the Real-World: The RAPID Registry

Safety of dupilumab in patients with severe asthma: real-life experience

Sequence of improvements in objective and patient-reported outcomes with dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps: Analysis of the SINUS-52 study

Severe Atopic Dermatitis and HyperEosinophilic Syndrome in Children Undergoing Dupilumab Treatment: Report of two cases

Severe asthma in pediatrics and Dupilumab after failure with Omalizumab

Should dupilumab be the standard first treatment choice for severe atopic dermatitis?

Study on the target level and influencing factors of dupilumab treatment in children with moderate to severe atopic dermatitis

Successful treatment of lichen amyloidosis with dupilumab treatment: a case report

Suspected EGPA in a patient on Dupilumab treatment: confirmed diagnosis of sarcoidosis – case report

Targeted Metabolomic Profiling as a Tool for Assessing Response to Biologicals: a case of Dupilumab in Severe Allergic Asthma

The Influence of Dupilumab on the Nasal and Gastrointestinal Microbiome in Diffuse Type 2 Chronic Rhinosinusitis

The successful resolve of nasal polyps in patient with dupilumab treatment

Treatment Patterns in Patients Who Initiated Dupilumab in a Real-World Clinical Setting: The RAPID Registry

Treatment of atopic dermatitis patients with dupilumab restores functional responses of circulating skin-homing CD4+ T and B cells

Treatment of severe atopic dermatitis in pediatric patients with Dupilumab and effects of therapy on nasal and skin microbiota: preliminary experimental evidence

Use of Corticosteroids and History of Surgery Among Patients with CRSwNP Initiating Dupilumab in the Global AROMA registry

Use of Dupilumab as Adjuvant Treatment in Oral Food Desensitization: A Case Report

Use of dupilumab in two pregnant women with nasal polyposis and severe persistent asthma: two case reports

Welcome

Only match titles

What are you looking for?

Knowledge Hub

Website

Only match titles

What are you looking for?

Knowledge Hub

Event Resources

Guidelines

Website

Sessions